AssetMark Inc’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

AssetMark Inc’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-8	Closed	-$1K	–	1461
2019 Q2	$1K	Buy	8 +2	+33%	+$179	﹤0.01%	1306
2019 Q1	$1K	Hold	6	–	–	﹤0.01%	1305
2018 Q4	$1K	Buy	+6	New	+$622	﹤0.01%	1381
2016 Q1	–	Sell	-10	Closed	-$1K	–	1451
2015 Q4	$1K	Buy	10 +7	+233%	+$1.19K	﹤0.01%	1295
2015 Q3	$0	Buy	+3	New	+$660	﹤0.01%	874

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

AssetMark Inc's ICPT Position: Q3 2019 in Review

AssetMark Inc sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2019, closing a stake of 8 shares — an estimated $1K sold.

AssetMark Inc first reported a position in ICPT in Q3 2015 and held it in 5 quarters. The position peaked at $1K in Q2 2019. 188 funds tracked by Wall St. Rank hold ICPT as of Q3 2019.

AssetMark Inc reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
AssetMark Inc sold 8 Intercept Pharmaceuticals, Inc. shares in Q3 2019, an estimated $1K.
AssetMark Inc first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2015 and held it in 5 quarters.
AssetMark Inc's Intercept Pharmaceuticals, Inc. position peaked at $1K in Q2 2019.
188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2019.

Based on AssetMark Inc's 13F filing for Q3 2019, filed 13 Nov 2019.